Clinical trial NCT04208789 - References

Resistance to Tuberculostatic Drugs — Artificial Inteligent for Diagnosing Drug-Resistant Tuberculosis

Citation(s)

•   Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P
  Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018 Jul 3;15(7):e1002595. doi: 10.1371/journal.pmed.1002595. eCollection 2018 Jul.
•   Collins D, Hafidz F, Mustikawati D
  The economic burden of tuberculosis in Indonesia. Int J Tuberc Lung Dis. 2017 Sep 1;21(9):1041-1048. doi: 10.5588/ijtld.16.0898.
•   Dande P, Samant P
  Acquaintance to Artificial Neural Networks and use of artificial intelligence as a diagnostic tool for tuberculosis: A review. Tuberculosis (Edinb). 2018 Jan;108:1-9. doi: 10.1016/j.tube.2017.09.006. Epub 2017 Sep 20. Review.
•   Darsey JA, Griffin WO, Joginipelli S, Melapu VK
  Architecture and biological applications of artificial neural networks: a tuberculosis perspective. Methods Mol Biol. 2015;1260:269-83. doi: 10.1007/978-1-4939-2239-0_17.
•   de O Souza Filho JB, de Seixas JM, Galliez R, de Bragança Pereira B, de Q Mello FC, Dos Santos AM, Kritski AL
  A screening system for smear-negative pulmonary tuberculosis using artificial neural networks. Int J Infect Dis. 2016 Aug;49:33-9. doi: 10.1016/j.ijid.2016.05.019. Epub 2016 May 24.
•   Dean AS, Cox H, Zignol M
  Epidemiology of Drug-Resistant Tuberculosis. Adv Exp Med Biol. 2017;1019:209-220. doi: 10.1007/978-3-319-64371-7_11. Review.
•   Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM
  The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.
•   Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione MC
  Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis. 2013 Aug;13(8):690-7. doi: 10.1016/S1473-3099(13)70130-0. Epub 2013 Jun 4.
•   Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M
  Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J. 2015 Jan;45(1):150-60. doi: 10.1183/09031936.00101814. Epub 2014 Sep 26.
•   GBD Tuberculosis Collaborators
  The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018 Mar;18(3):261-284. doi: 10.1016/S1473-3099(17)30703-X. Epub 2017 Dec 7.
•   Kendall EA, Azman AS, Cobelens FG, Dowdy DW
  MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS One. 2017 Mar 8;12(3):e0172748. doi: 10.1371/journal.pone.0172748. eCollection 2017.
•   Prada-Medina CA, Fukutani KF, Pavan Kumar N, Gil-Santana L, Babu S, Lichtenstein F, West K, Sivakumar S, Menon PA, Viswanathan V, Andrade BB, Nakaya HI, Kornfeld H
  Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications. Sci Rep. 2017 May 17;7(1):1999. doi: 10.1038/s41598-017-01767-4.
•   Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW
  Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect. 2018 Dec;77(6):469-478. doi: 10.1016/j.jinf.2018.10.004. Epub 2018 Oct 16.
•   Soeroto AY, Lestari BW, Santoso P, Chaidir L, Andriyoko B, Alisjahbana B, van Crevel R, Hill PC
  Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study. PLoS One. 2019 Feb 28;14(2):e0213017. doi: 10.1371/journal.pone.0213017. eCollection 2019.
•   Souza Filho JBOE, Sanchez M, Seixas JM, Maidantchik C, Galliez R, Moreira ADSR, da Costa PA, Oliveira MM, Harries AD, Kritski AL
  Screening for active pulmonary tuberculosis: Development and applicability of artificial neural network models. Tuberculosis (Edinb). 2018 Jul;111:94-101. doi: 10.1016/j.tube.2018.05.012. Epub 2018 May 19.
•   Tegegne BS, Mengesha MM, Teferra AA, Awoke MA, Habtewold TD
  Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. Syst Rev. 2018 Oct 15;7(1):161. doi: 10.1186/s13643-018-0828-0.
•   van Kampen SC, Susanto NH, Simon S, Astiti SD, Chandra R, Burhan E, Farid MN, Chittenden K, Mustikawati DE, Alisjahbana B
  Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study. PLoS One. 2015 Jun 15;10(6):e0123536. doi: 10.1371/journal.pone.0123536. eCollection 2015.
•   Wang MG, Huang WW, Wang Y, Zhang YX, Zhang MM, Wu SQ, Sandford AJ, He JQ
  Association between tobacco smoking and drug-resistant tuberculosis. Infect Drug Resist. 2018 Jun 12;11:873-887. doi: 10.2147/IDR.S164596. eCollection 2018. Review.

Artificial Neural Network as Diagnostic Tools For Rifampicin-Resistant Tuberculosis In Indonesia: A Predictive Model Study and Economic Evaluation

Details for clinical trial NCT04208789